Pfizer Inc. announced complete results from a Phase III, 12-week, pivotal study (JADE MONO-1) of PF 04965842 (abrocitinib) in patients...
Clovis Oncology announced positive top-line data from the monotherapy arm of the phase III ATHENA (GOG 3020/ENGOT-ov45) trial (ATHENA-MONO) demonstrating that Rubraca (rucaparib) as maintenance treatment for ovarian cancer successfully achieved the primary endpoint of significantly improved investigator-assessed progression-free survival (PFS) compared with placebo.
Pfizer Inc. announced that JAMA Dermatology has published complete results from the second Phase III monotherapy pivotal study (JADE MONO-2) of PF 04965842 (abrocitinib), an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor, in patients aged 12 and older with moderate to severe atopic dermatitis (AD).
Merck in partnership with Pfizer Inc. announced that two Phase III studies (VERTIS Mono and VERTIS Factorial) of ertugliflozin, an...
Sanofi and Regeneron announced Phase III ODYSSEY MONO trial results with alirocumab,, an investigational monoclonal antibody, targeting PCSK 9 (proprotein...
Aim: This phase III, multicentre, randomized study (ClinicalTrials.gov; NCT01958671) evaluated the efficacy and safety of ertugliflozin monotherapy in adults with inadequately controlled type 2 diabetes (glycated haemoglobin [HbA1c], 7.0% to 10.5% [53-91 mmol/mol]) despite diet and exercise.
Objective: To evaluate clinical efficacy, safety, and tolerability of levetiracetam as mono- or adjunctive therapy in the treatment of children and adolescents with epilepsy.
This trial will evaluate the efficacy and safety of ertugliflozin monotherapy in the treatment of participants with type 2 diabetes mellitus (T2DM) and inadequate glycemic control on diet and exercise.